Seattle Genetics targets third disease with SGN-40

Seattle Genetics Inc. (NASDAQ: SGEN - News) announced it is targeting a third condition with its SGN-40 cancer treatment. It has reported early clinical trials of SGN-40 for chronic lymphocytic leukemia (CLL).

The FDA has granted an orphan drug designation for treatment for CLL. SGN-40 previously received orphan drug designation for multiple myeloma. In December 2004, the company began clinical trials of SGN-40 on patients with non-Hodgkin's lymphoma.

For more info on SGN-40
http://myelomic.blogspot.com/2005/05/seattle-genetics-update-on-sgn-40.html